SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001209191-22-060117
Filing Date
2022-12-06
Accepted
2022-12-06 19:05:49
Documents
1
Period of Report
2022-12-01

Document Format Files

Seq Description Document Type Size
1 FORM 4/A SUBMISSION doc4a.html 4/A  
1 FORM 4/A SUBMISSION doc4a.xml 4/A 5244
  Complete submission text file 0001209191-22-060117.txt   6645
Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address
Nau Jeffrey (Reporting) CIK: 0001791159 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-39112 | Film No.: 221448865